scholarly journals Frequency of Hematologic and Solid Malignancies in the Family History of Patients with Myeloid Neoplasms

2022 ◽  
Author(s):  
Alaa Ali ◽  
Batool Yassin ◽  
Ali Almothaffar
Keyword(s):  
Acute Myeloid Leukemia ◽  
Family History ◽  
Myelodysplastic Syndrome ◽  
Aplastic Anemia ◽  
Myeloid Leukemia ◽  
Myeloid Neoplasms ◽  
Solid Malignancies ◽  
History Of ◽  
Acute Myeloid ◽  
Second Degree

Background: Studies demonstrated that there are several germline mutations that lead to a familial predisposition for acute myeloid leukemia and Myelodysplastic syndrome. According to the American Society of Clinical Oncology, the minimum cancer family history was defined as including first- and second-degree family history, type of primary cancer, and age at diagnosis. The current study aimed to estimate the frequency of positive family history for hematologic and solid malignancies in patients with Myeloid Neoplasms / Aplastic anemia. Patients and Methods: A cross-section study was carried out at the Center of Blood Diseases, Medical City Campus during the period from March-December 2020. A purposeful sample of all adult patients with Myeloid Neoplasms [Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia, and Aplastic Anemia] was included in the study. A data collection form was prepared, based on the Hereditary Hematopoietic Malignancies Screening form adopted by the University of Chicago, and modified by the researchers; The data were collected by direct interview with the patients. Patients with hematologic malignancy and one or more first-degree relatives, or ≥2 second-degree relatives, with hematologic malignancies and individuals with Myelodysplastic Syndrome or Acute Myeloid Leukemia and two first or second-degree relatives with a diagnosis of solid tumor malignancy, were considered potential carriers of such genetic predisposition. Results: A total of 153 patients were included; males were nearly equal to females with a male to female ratio of nearly 1:1. Acute Myeloid Leukemia was found in 57.5%, Aplastic Anemia was found in 19%, Chronic Myeloid Leukemia in 17% and only four patients (6.5%) were known cases of Myelodysplastic Syndrome. Nine patients (5.9%) reported a family history of hematological malignancies, 29 (19.0%) reported a family history of solid malignancies and only one patient reported a family history of both hematological and solid malignancies. Regarding the official medical reports of the patients, no patient had been interviewed properly about this crucial point. Conclusion: Positive family history for hematological and solid malignancies in Iraqi patients with myeloid neoplasms is prevalent. Our current approach to this critical issue in Iraq needs to be re-considered.

scholarly journals Frequency of hematologic and solid malignancies in the family history of 50 patients with acute myeloid leukemia – a single center analysis

PLoS ONE ◽  
2019 ◽  
Vol 14 (4) ◽  
pp. e0215453 ◽  
Author(s):  
Anne-Sophie Sandner ◽  
Ramona Weggel ◽  
Yasmin Mehraein ◽  
Stephanie Schneider ◽  
Wolfgang Hiddemann ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Family History ◽  
Myeloid Leukemia ◽  
Single Center ◽  
Solid Malignancies ◽  
The Family ◽  
History Of ◽  
Acute Myeloid

scholarly journals Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner?

2019 ◽  
Vol 2019 ◽  
pp. 1-4
Author(s):  
M. Malagola ◽  
N. Polverelli ◽  
V. Cancelli ◽  
E. Morello ◽  
A. Turra ◽  
...  
Keyword(s):  
Risk Factors ◽  
Acute Myeloid Leukemia ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
Clinical Risk Factors ◽  
Decision Algorithm ◽  
Platelet Recovery ◽  
Clinical Risk ◽  
History Of ◽  
Acute Myeloid

We present a case of a patient with a three-month history of peripheral blood cytopenia without a confirmed diagnosis of myelodysplastic syndrome, who developed a favourable-risk acute myeloid leukemia (AML), according to the European Leukemia Net (ELN) criteria. The patient achieved a complete remission with incomplete platelet recovery (CRi) after induction. The patient achieved the morphological CR after the first consolidation and completed the first-line treatment with a syngeneic stem cell transplantation (SCT). A disease relapse occurred after one year of CR (blast cell count in the bone marrow 15%), and the patient was offered a haplo-SCT, which he refused due to personal reasons. In this paper, we discuss the interplay between clinical and biological risk factors in non-high-risk AML patients and speculate that some old clinical risk factors (e.g., age of the patient, achievement of CR after induction, and previous history of myelodysplastic syndrome) may still impact on the treatment decision algorithm of some of these patients.

Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 2659-2659
Author(s):  
Luana Fianchi ◽  
Maria Teresa Voso ◽  
Anna Candoni ◽  
Gianluca Gaidano ◽  
Marianna Criscuolo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Acute Myeloid Leukemia ◽  
Autoimmune Disease ◽  
Solid Tumor ◽  
Myeloid Leukemia ◽  
Median Latency ◽  
Primary Malignancy ◽  
Myeloid Neoplasms ◽  
History Of ◽  
Acute Myeloid

Abstract Introduction In 2001, the World Health Organization (WHO) recognized therapy-related myeloid neoplasms (t-MN) as a distinct entity including acute myeloid leukemia (AML) and myelodisplastic syndromes (MDS). At present, about 10% of all AML patients have a previous history of exposure to chemotherapy and/or radiation for a primary malignancy or autoimmune disease. In 2009, we initiated a Web-based epidemiological registry, with the purpose of collecting t-MN diagnosed at Italian Hematological or Oncological Divisions. Methods Demographic and clinical information on t-MN patients were included in the database whose access was restricted to selected users and was password-protected. Between May 2009 and June 2013, 279 t-MN patients [121 males and 158 females; median age 64 years (range 23-88 years)], observed at 22 Italian Centers between 1999 and 2012, were registered in the web-database. Results The primary malignancy (PM) was a hematological neoplasm (HM) in 123 cases (44%), a solid tumor in 145 cases (52%), and an autoimmune disease in 11 patients (4%). Twenty patients (7%) had a history of two or more previous cancers. Among hematological malignancies, the most frequent PM were lymphoproliferative diseases (92/122 cases), while breast cancer (65/146 cases) was the most frequent primary solid tumor. In particular, hematological PM were: 92 lymphoprolipherative diseases (68 Non Hodgkin and 18 Hodgkin lymphoma, 6 chronic lymphocytic leukemia); 12 Multiple myeloma; 14 myeloproliferative neoplasms (7 Myelofibrosis; 3 polycitemia vera; 3 essential thrombocythemia; 1 Hypereosinophilic syndrome.); 1 Acute lymphoblastic leukemia; 4 Acute myeloid leukemia (acute promielocytic leukemia in 2 cases). Sites of primary solid tumors were: 65 Breast; 32 Uro-genital (14 prostate; 5 bladder; 8 uterus; 5 ovarium); 17 Colon-rectal; 8 Lung; 8 Thyroid; 15 others (2 stomach; 5 CNS; 2 skin, 4 oropharynx; 2 sarcoma). Eleven patients had previously received immunosuppressive therapy for an autoimmune disease (5 with mitoxantrone, 5 with methotrexate, 1 with chlorambucil). Two-hundred-thirty-six patients had previously received chemotherapy for their primary malignancy, associated to radiotherapy (RT) in 94 cases. RT represented the only primary treatment in 43 cases. Median latency between PM and t-MN was 5.6 years (range 0.5-48). There were no differences between t-MN after lymphoprolipherative diseases or after breast cancer when considering patients’ age (p=0.09) or median latency (p 0.20) between PM and t-MN. According to morphology, t-MN were classified as 164 AML, 108 MDS and 7 ALL. Karyotype was available for 204 patients and was unfavorable in 81 patients (complex in 54 patients including del(7) in 19 cases; 15 cases with isolated del(7)]. A recurrent chromosomal translocation was present in 13 patients [1 t(8;21), 8 t(15;17) and 1 inv(16); 3 t(9;22)], while 75 patients had a normal karyotype. One-hundred-thirty-five patients received chemotherapy for t-MN, while the hypomethylating drug Azacitidine was administered to 63 patients. Fifty-six patients underwent bone marrow transplantation (45 allogeneic and 11 autologous). Median OS from the t-MN diagnosis was 7.7 months (range 0.2-158+). Conclusions The incidence of t-MN is rising as a result of the increasing number of cancer survivors. Lymphoprolipherative diseases and breast cancer are the most common primary malignancies at risk of developing a therapy-related myeloid neoplasm. Disclosures: Santini: Novartis: Honoraria; Janssen : Honoraria; Celgene: Honoraria; gsk: Honoraria.

Aplastic anemia evolving into overt myelodysplastic syndrome/acute myeloid leukemia with t(3;5)(p25;q31)

2002 ◽  
Vol 137 (2) ◽  
pp. 91-94 ◽  
Author(s):  
Eri Kawata ◽  
Junya Kuroda ◽  
Shinya Kimura ◽  
Yuri Kamitsuji ◽  
Yutaka Kobayashi ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myelodysplastic Syndrome ◽  
Aplastic Anemia ◽  
Myeloid Leukemia ◽  
Acute Myeloid

scholarly journals Acquired hemoglobin H disease in a patient with aplastic anemia evolving into acute myeloid leukemia

2004 ◽  
Vol 122 (6) ◽  
pp. 273-275 ◽  
Author(s):  
Maria Stella Figueiredo ◽  
Perla Vicari ◽  
Eliza Yuriko Sugano Kimura ◽  
Sandra Vallin Antunes ◽  
Mihoko Yamamoto
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myelodysplastic Syndrome ◽  
Aplastic Anemia ◽  
Myeloid Leukemia ◽  
Fetal Hemoglobin ◽  
First Case ◽  
Brazilian Patient ◽  
Long Term Follow Up ◽  
Acute Myeloid

CONTEXT: The prognosis of severe aplastic anemia has improved since the introduction of bone marrow transplantation and treatment with antithymocyte globulin. In contrast to the success of these protocols, studies with long term follow-up have shown the occurrence of clonal diseases such as paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome and acute leukemia in aplastic anemia. CASE REPORT: We report the first case of a Brazilian patient with aplastic anemia who developed myelodysplastic syndrome and acute myeloid leukemia showing acquired hemoglobin H and increased fetal hemoglobin.

Sign in / Sign up

Export Citation Format

Share Document